Showing results (11-20 of 416) with videos related to
Sort By:
Pageof 42
Oncogene|October 7, 2003
Epigenetic targets in hematopoietic malignanciesRainer Claus, Michael LübbertCritical Reviews in Oncology/Hematology|May 12, 2005
DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical resultsWerner Digel, Michael LübbertSeminars in Hematology|July 15, 2005
Decitabine in acute myeloid leukemiaMichael Lübbert, Mark MindenSeminars in Hematology|March 31, 2019
Can we predict responsiveness to hypomethylating agents in AML?Julia Stomper, Michael LübbertAnnals of Hematology|April 3, 2025
Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myelomaPaul Mobascher, Monika Engelhardt, Ralph WäschCurrent Opinion in Oncology|August 2, 2017
Elderly patients with multiple myeloma: towards a frailty approach?Sonja Zweegman, Monika Engelhardt, Alessandra Larocca, et al.Frontiers in Genetics|July 14, 2022
The Role of the APC/C and Its Coactivators Cdh1 and Cdc20 in Cancer Development and TherapyChristine Greil, Monika Engelhardt, Ralph WäschAnnals of Hematology|November 26, 2005
The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasiaHans Eckart Schaefer, Michael LübbertSeminars in Hematology|October 20, 2012
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an updateTina E Joeckel, Michael LübbertCancer Cell|March 28, 2025
All-trans retinoic acid beyond acute promyelocytic leukemiaUsama-Ur Rehman, Michael LübbertPageof 42